Travere Therapeutics, Inc. TVTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $127.2M-1.9% | $129.69M-21.3% | $164.86M+44.0% | $114.45M+40.0% | $81.73M+9.3% | ||
| $1.95M-23.6% | $2.55M+61.1% | $1.59M+4.2% | $1.52M-67.5% | $4.68M+83.3% | ||
| $125.25M-1.5% | $127.14M-22.1% | $163.27M+44.6% | $112.93M+46.6% | $77.05M+6.7% | ||
| 98.5%+0.4pp | 98%-1.0pp | 99%+0.4pp | 98.7%+4.4pp | 94.3%-2.3pp | ||
| $57.09M-1.3% | $57.87M+11.5% | $51.89M+5.1% | $49.36M+5.3% | $46.89M-24.5% | ||
| $80.25M-21.1% | $101.69M+17.6% | $86.45M+13.4% | $76.22M+26.2% | $60.41M-13.1% | ||
| $164.11M+1.2% | $162.12M+15.9% | $139.93M+10.1% | $127.1M+2.2% | $124.41M-8.2% | ||
| -$36.92M-13.8% | -$32.43M-230% | $24.93M+297% | -$12.65M+70.4% | -$42.67M+29.7% | ||
| -29%-4.0pp | -25%-40.1pp | 15.1%+26.2pp | -11.1%+41.2pp | -52.2%+29.0pp | ||
| $2.3M+0.2% | $2.3M-16.5% | $2.75M-3.3% | $2.85M-0.4% | $2.86M+1.4% | ||
| $2.58M-0.3% | $2.59M-14.9% | $3.05M-7.3% | $3.29M-13.4% | $3.8M0.0% | ||
| $193K-98.3% | $11.36M+1,351% | $783K+1,021% | -$85K-106% | $1.49M+275% | ||
| -$36.72M-74.3% | -$21.07M-182% | $25.71M+302% | -$12.74M+69.1% | -$41.19M+31.7% | ||
| -$120K-113% | $921K+11,413% | $8K-60.0% | $20K-48.7% | $39K— | ||
| -$37.1M— | —— | $25.71M+302% | -$12.76M+69.1% | -$41.23M+31.6% | ||
| -29.2%— | —— | 15.6%+26.7pp | -11.1%+39.3pp | -50.4%+30.1pp | ||
| -$36.6M— | —— | $25.71M+18,361,428,671% | -$0.14+100.0% | -$41.23M— | ||
| -$0.40— | —— | $0.28+300% | -$0.14+70.2% | -$0.47+33.8% | ||
| -$0.40— | —— | $0.29+307% | -$0.14+70.2% | -$0.47+33.8% | ||
| 91.9M+3.0% | 89.2M-13.1% | 102.6M+15.4% | 88.9M+0.7% | 88.4M+12.0% | ||
| 91.9M+3.0% | 89.2M0.0% | 89.2M+0.3% | 88.9M+0.7% | 88.4M+12.0% | ||
| $24.82M— | —— | —— | —— | $12.43M— | ||
| -$36.98M— | $0-100% | $25.46M+300% | -$12.72M+69.7% | -$41.99M+29.2% | ||
| -$36.6M-66.5% | -$21.99M-186% | $25.71M+302% | -$12.76M+69.1% | -$41.23M+31.6% | ||
| -$91K-101% | $11.07M+2,172% | $487K+193% | -$526K-196% | $549K+194% | ||
| $57.09M-1.3% | $57.87M+11.5% | $51.89M+5.1% | $49.36M+5.3% | $46.89M-24.5% | ||
| $127.2M-1.9% | $129.69M-21.3% | $164.86M+44.0% | $114.45M+40.0% | $81.73M+9.3% | ||
| -$36.92M-13.8% | -$32.43M-230% | $24.93M+297% | -$12.65M+70.4% | -$42.67M+29.7% | ||
| -$11.7M+18.1% | -$14.29M-135% | $40.72M+2,881% | $1.37M+105% | -$29.87M+38.6% | ||
| -$11.7M+18.1% | -$14.29M-135% | $40.72M+2,881% | $1.37M+105% | -$29.87M+38.6% | ||
| -9.2%+1.8pp | -11%-35.7pp | 24.7%+23.5pp | 1.2%+37.7pp | -36.5%+28.5pp | ||
| -$36.92M-13.8% | -$32.43M-230% | $24.93M+297% | -$12.65M+70.4% | -$42.67M+29.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Travere Therapeutics, Inc.'s profit margins?
- Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.
- Where does Travere Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.